Changes in Health-Related Quality of Life in Patients with Therapy-Resistant Migraine during Treatment with Erenumab in an Ambulatory Care Setting

Migraine preventive treatment with the CGRP-receptor monoclonal antibody Erenumab can positively impact health-related quality of life (HRQoL) and disease-associated disability. Patient-reported outcome measures (PROMs) are a valuable additional datapoint to real-world evidence covering how treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Haneke, Hannah, Sulaiman, Schirin, Nickel, Sina, Raffaelli, Bianca, Jansen, Jan-Peter, Kirchberger, Valerie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488376/
https://www.ncbi.nlm.nih.gov/pubmed/37685685
http://dx.doi.org/10.3390/jcm12175619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488376/
https://www.ncbi.nlm.nih.gov/pubmed/37685685
http://dx.doi.org/10.3390/jcm12175619

Ejemplares similares